Comparison of \textsuperscript{68}Ga-PSMA-11 PET-CT with mpMRI for preoperative lymph node staging in patients with intermediate to high-risk prostate cancer

Qing Zhang\textsuperscript{1}\textsuperscript{†}, Shiming Zang\textsuperscript{2}\textsuperscript{†}, Chengwei Zhang\textsuperscript{1}\textsuperscript{†}, Yao Fu\textsuperscript{3}, Xiaoyu Lv\textsuperscript{1}, Qinglei Zhang\textsuperscript{4}, Yongming Deng\textsuperscript{1}, Chuan Zhang\textsuperscript{2}, Rui Luo\textsuperscript{2}, Xiaozhi Zhao\textsuperscript{1}, Wei Wang\textsuperscript{1}, Feng Wang\textsuperscript{2⋆} and Hongqian Guo\textsuperscript{1⋆}

Abstract

**Background:** To evaluate the diagnostic value of \textsuperscript{68}Ga-PSMA-11 PET-CT with multiparametric magnetic resonance imaging (mpMRI) for lymph node (LN) staging in patients with intermediate- to high-risk prostate cancer (PCA) undergoing radical prostatectomy (RP) with pelvic lymph node dissection (PLND).

**Methods:** We retrospectively identified 42 consecutive patients with intermediate- to high-risk PCAs according to D’Amico and without concomitant cancer. Preoperative \textsuperscript{68}Ga-PSMA-11 PET-CT, pelvic mpMRI and subsequent robot assisted laparoscopic RP with PLND were performed in all patients.

**Results:** Among 42 patients assessed, the preoperative PSA value, Gleason score, pT stage and intraprostatic PCA volume of patients with LN metastases were all significantly higher than those without metastases (\(P = 0.029, 0.028, 0.004\), respectively). The average maximum standardized uptake value (SUV) of \textsuperscript{68}Ga-PSMA-11 PET-CT positive PCA of patients with or without LN metastases were 13.10 (range 6.12–51.75) and 7.22 (range 5.4–11.2), respectively (\(P < 0.001\)). \textsuperscript{68}Ga-PSMA-11 PET-CT and pelvic mpMRI had the ability of succeed on preoperative definite accurate diagnosis and accurate localization of primary PCA in all 42 patients. Fifteen patients (35.71%) had a pN1 stage. 51 positive LN were found. Both \textsuperscript{68}Ga-PSMA-11 PET-CT and pelvic mpMRI displayed brilliant patient-based and region-based sensitivity, specificity, negative predictive value and positive predictive value. There was no statistical difference for the detection of LNMs according to the diameter of the LNMs between \textsuperscript{68}Ga-PSMA-11 PET-CT and mpMRI in this study.

**Conclusions:** Both \textsuperscript{68}Ga-PSMA-11 PET-CT and mpMRI performed great value for LN staging in patients with intermediate- to high-risk PCAs undergoing RP with PLND. However, despite excellent performance of \textsuperscript{68}Ga-PSMA-11 PET-CT, it cannot replace mpMRI that remains excellent for lymph node staging.

**Keywords:** Prostate cancer, PSMA, PET-CT, mpMRI, Lymph node staging
Background
Prostate cancer (PCa) is the most common tumor in men around the United States and Europe [1]. Radical prostatectomy (RP) is the most widely used form of treatment for patients with localized PCa [2]. Lymph node (LN) status is an important prognostic factor for a newly diagnosed PCa [3]. Current guidelines recommend computed tomograph (CT) or conventional magnetic resonance imaging (MRI, T1W and T2W sequences) to evaluate metastatic spread to LN prior to RP, especially for intermediate- or high-risk PCa [4]. However, these staging modalities depend solely on morphologic information and LN involvement is mainly assessed by size [5]. Thus, these techniques yielded relatively poor specificity for evaluating LN status.

Multiparametric MRI (mpMRI) with its best soft tissue resolution plays an important role in the management of patients with PCa [6]. It contains T1- and T2-high-resolution weighted imaging, diffusion-weighted imaging (DWI), dynamic contrast-enhanced (DCE) and other functional MRI techniques. DWI provided information on tissue cellular density and membrane integrity while DCE enabled visualization of vascular permeability and perfusion [7]. The incorporation of these newer sequences allows functional tissue information to supplement the anatomic information provided by T1W and T2W sequences [7], which was widely used for PCa diagnosis, localization, staging. It is believed that mpMRI is more accurate for PCa diagnosis and LN status assessment than conventional MRI (T1W and T2W sequences). Thus, it was considered to be a promising technique for LN status assessment.

Recently, ligands of the prostate-specific membrane antigen (PSMA) have been introduced in positron emission tomography (PET) imaging of PCa, targeting an extracellular domain of this transmembraneous cell-surface protein [8, 9]. PSMA is almost exclusively expressed in prostate tissue and either if they were oblong with a short-axis diameter > 10 mm or were rounded with a short-axis > 8 mm or if they showed restricted diffusion on the DWI and ADC map or increased contrast enhancement.

Methods
Patients
From March 2017 to July 2017, forty-two consecutive patients with intermediate- to high-risk PCa according to D’Amico and without concomitant cancer who underwent ⁶⁸Ga-PSMA-11 PET-CT imaging, pelvic mpMRI and subsequent robot assisted laparoscopic RP with PLND at our institution were included into the study. Seventeen (40.48%) patients had intermediate risk and 25 (59.52%) patients had high risk PCa at PLND. All patients gave written informed consent for the purpose of anonymized evaluation and publication of their data. The retrospective analysis was approved by the Ethics Committee of the Drum Tower Hospital, Medical School of Nanjing University (Reference: DT2017028).

MpMRI examination and analysis
Pelvic mpMRI was performed with a 3.0-T MR scanner (Achieva 3.0 T TX, Philips Medical Systems, The Netherlands) by using a 16-channel phased array coil as described previously [11, 12]. Transverse/coronal/sagittal (18 slices, thickness 3 mm/gap 0.5 mm, TR 3744 ms, TE 120 ms, number of signals acquired 2, resolution 1.49 mm × 1.51 mm) T2-weighted turbo spin-echo (TSE) images were acquired. DWI, spin-echo echo-planar images (18 slices, thickness 3 mm, intersection gap 1 mm, TR 925/TE 41 ms, number of signals acquired 1, resolution 3 mm × 3 mm, b-factor 0/800/1500 s/mm²) were acquired. And T1 high-resolution isotropic volume with fat suppression after gadolinium injection was employed for DCE images (133 slices, thickness 3 mm, no intersection gap, TR 3.1/TE 1.46 ms, number of signals acquired 1, resolution 1.49 mm × 1.51 mm, dynamic scan time 00:06.9). Mappings of the ADC were generated from b 0, b 800 and b 1500 images of DWI using the Philips WorkStation software (Extended Workspace, EWS). All MRI scans were reviewed by an experienced radiologist with no prior clinical information. LNs were classified as malignant if lying in the territory of drainage of prostatic tumors and either if they were oblong with a short-axis diameter > 10 mm or were rounded with a short-axis > 8 mm or if they showed restricted diffusion on the DWI and ADC map or increased contrast enhancement.

⁶⁸Ga-PSMA-11 PET-CT examination and analysis
The ⁶⁸Ga-PSMA-11 was synthesized with an ITG semi-automated module (Germany, Munich) as described previously [13]. ⁶⁸Ga-PSMA-11 was stable in vitro, its radiochemical purity was > 99% after 2 h of radiolabeling.
All patients underwent PET-CT in a uMI 780 PET-CT scanner (United Imaging Healthcare (UIH), Shanghai, China) 60 min after intravenous injection of 68Ga-PSMA-11 (median, 131.72 MBq, range 130.6–177.6 MBq). First, a CT scan (130 keV, 80 mAs) was obtained without using contrast medium. Static emission scans, corrected for dead time, scatter and decay, were acquired from the vertex to the proximal legs. This required the patient assume 4 bed positions with 2 min per bed position. The images were iteratively reconstructed and included CT-based attenuation correction with the OSEM algorithm using 4 iterations with 8 subsets and Gaussian filtering to an in-plane spatial resolution of 5 mm at full-width at half-maximum. For calculation of the standardized uptake value (SUV), circular regions of interest were drawn around the area with focally increased uptake in transaxial slices and automatically adapted to a three-dimensional volume of interest using UIH WorkStation software (United Imaging Healthcare) at 50% isocontour. Datasets were fully corrected for random coincidences, scatter radiation, and attenuation. Images were interpreted by three experienced nuclear medicine physicians based on visual assessment. Final decisions were reached by consensus. A positive scan was defined as one showing abnormal focal increases in tracer activity within a lesion with an intensity level higher against a surrounding background considered to be malignant. The uptake of 68Ga-PSMA-11 was quantified SUV_{max}. 

Surgery
All patients underwent robot assisted laparoscopic RP with a bilateral meticulous template PLND (dissection of all nodes surrounding the common iliac, external iliac, and internal iliac vessels, in the obturator fossa, and in the presacral region). The LN specimens were prospectively mapped and labelled separately on a standardized LN map according to their origin (confer surgery). Positive LNs at imaging were recorded on the same standardised LN map. The histopathologic analysis of the LNs served as the reference to which the corresponding anatomic sites on preoperative imaging were compared. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for LN status of 68Ga-PSMA-11 PET-CT and mpMRI were calculated, respectively. 
P < 0.05 were considered significant. Statistical analysis was carried out with SPSS v. 21 (SPSS INC., Chicago, Ill).

Results
Patient characteristics are summarized in Table 1. The mean age of patients was 68.86 years (range 55–82). The mean PSA value was 52.31 ng/mL (range 7.20–151.00). The PSA value of patients with (n = 27) LN metastases were 79.63 ng/mL (range 10.95–348.00) and 37.14 ng/mL (range 7.20–128.40), respectively (P = 0.029). The Gleason score (P = 0.028) and pT stage (P = 0.004) at RP in patients with LN metastases were both significantly higher than those without LN metastases. Intraprostatic PCa volume in patients with LN metastases was significantly larger than those without LN metastases (P = 0.008). The average maximum SUV of 68Ga-PSMA-11 PET-CT positive PCa of patients with and without LN metastases were 13.10 (range 6.12–51.75) and 7.22 (range 5.4–11.2), respectively (P < 0.001). Figure 1 displayed the image of preoperative pelvic mpMRI and 68Ga-PSMA-11 PET-CT. Figure 1A–D demonstrated the suspicious lesions on different mpMRI sequences (T2WI, DWI, ADC, DCE, respectively). Figure 1E–G presented the 68Ga-PSMA-11 PET-CT image, which was in accord with the MRI results. The histological sections of the whole prostate gland confirmed the location of tumor lesions (Fig. 1H). Therefore, 68Ga-PSMA-11 PET-CT and pelvic mpMRI succeed on preoperative definite diagnosis and accurate localization of primary PCa in all 42 patients.

In total, 621 LNs in all 42 patients were resected with a mean number of 7.095 nodes per patient (range 2–15).
Table 1 Patient characteristics (n = 42) stratified by nodal status

|                          | Total patients (n = 42) | No LN metastases (n = 27) | LN metastases (n = 15) | P value |
|--------------------------|-------------------------|---------------------------|------------------------|---------|
| Age, year, mean, median (range) | 68.86, 69 (55–82) | 69.26, 69 (55–82) | 70.93, 74 (55–79) | 0.503   |
| PSA, ng/ml, mean, median (range) | 52.31, 37.25 (7.20–348.00) | 37.14, 23.50 (7.20–128.40) | 79.63, 54.30 (10.95–348.00) | 0.029   |
| Gleason score at RP (%) |                          |                          |                        | 0.028   |
| 3 + 4                     | 9 (21.43)               | 9 (33.33)                 | 0 (0)                  |         |
| 4 + 3                     | 9 (21.43)               | 6 (22.22)                 | 3 (20.00)              |         |
| ≥ 4 + 4                   | 24 (57.14)              | 12 (44.44)                | 12 (80.00)             |         |
| pT stage at RP, no. (%)   |                          |                          |                        | 0.004   |
| pT2                       | 11 (26.19)              | 11 (40.74)                | 0 (0)                  |         |
| pT3a                      | 8 (19.05)               | 6 (22.22)                 | 2 (13.33)              |         |
| pT3b                      | 23 (54.76)              | 10 (37.04)                | 13 (86.67)             |         |
| Intraprostastic PCa size, cm, mean, median (range) | 2.72, 2.55 (0.70–5.30) | 2.43, 2.30 (0.70–4.30) | 3.24, 3.2 (1.00–5.30) | 0.828   |
| Intraprostastic PCa volume, ml, mean, median (range) | 10.04, 5.46 (0.13–49.00) | 6.84, 4.33 (0.126–31.046) | 15.86, 9.46 (0.32–48.99) | 0.008   |
| LNs removed, no. (%)      | 621 (100)               | 381 (61.35)               | 240 (38.65)            |         |
| LNM removed, no. (%)      | 51 (100)                | –                         | 51 (100)               |         |
| Short-axis diameter < 5 mm | 0                      | –                         | –                      |         |
| Short axis diameter 5–10 mm | 9                      | –                         | 9                      |         |
| Short-axis diameter > 10 mm | 42                     | –                         | 42                     |         |
| Intranodal LNM size, mm², mean, median (range) | 14.67, 13.00 (7–31) | –                         | 14.67, 13.00 (7–31) | –       |
| Overall LNM size, mm², mean, median (range) | 28.87, 30.00 (16–45) | –                         | 28.87, 30.00 (16–45) | –       |
| SUV, maximal LN, mean, median (range) | 7.35, 5.40 (4.5–27.72) | –                         | 7.35, 5.40 (4.5–27.72) | –       |
| SUV, maximum PCa, mean, median (range) | 9.32, 7.60 (5.4–51.75) | 7.22, 6.7 (5.4–11.2) | 13.10, 8.12 (6.12–51.75) | < 0.001 |

LN lymph node, LNM lymph node metastasis, PCa prostate cancer, PSA prostate specific antigen, PSMA prostate-specific membrane antigen, RP radical prostatectomy, SUV standardized uptake value

* Largest/index lymph node per patient is presented

Fig. 1 Excellent concordance between mpMRI, ⁶⁸Ga-PSMA-11 PET-CT and whole-gland pathology analysis of a prostate cancer (Gleason score 4 + 5 = 9/10). T2WI (A), DWI (B), ADC (C), DCE (D), CT image (E), ⁶⁸Ga-PSMA-11 PET (F), ⁶⁸Ga-PSMA-11 PET/CT (G) and Histological analyses of whole-gland sections revealed pT3a PCa with Gleason score 9 (4 + 5) (H)
Fifteen patients (35.71%) had a pN1 stage, which corresponded to a total of 51 of 621 LNs (8.21%). The numbers of LNMs with short axis diameter 5–10 mm and LNMs with short axis diameter > 10 mm were nine and forty-two, respectively. Fifteen (29.41%), 20 (39.22%), 11 (21.57%), and 5 (9.80%) positive LNs were found along the obturator fossa, external iliac vessels, internal iliac vessels, and common iliac vessels, respectively. No positive LNs were found along the presacral fossa in this study (Table 2).

Figure 2 displayed positive lymph node at the left internal iliac and obturator fossa on pelvic mpMRI image (A–E, Axial T2WI, DWI, ADC and coronal fat suppression T2WI sequences, respectively) and ⁶⁸Ga-PSMA-11 PET-CT image (F–H). Figure 2I, J presented the histological result of the lymph node, which proved that the lymph node was positive. Table 3 showed the number of correctly and falsely recognized cases, the results of the primary objectives on a patient-based and a LN region-based analysis for ⁶⁸Ga-PSMA-11 PET-CT and mpMRI, respectively (Fig. 2). ⁶⁸Ga-PSMA-11 PET-CT presented a patient-based sensitivity, specificity, PPV and NPV of 93.33, 96.30, 93.33 and 96.30%, respectively. ⁶⁸Ga-PSMA-11 PET-CT showed a LN region-based sensitivity, specificity, PPV and NPV of 96.08, 99.65, 96.08 and 99.65%, respectively. Results of ROC analysis showed that there is significant difference between those two groups (Histopathology positive LN and Histopathology negative LN) (P < 0.001). Area under the curve is 0.993 (95% CI 0.988–0.999) and the best cut-off (SUV max > 3.25) has a sensitivity of 85.7% and a specificity of 99.8%. Moreover, mpMRI demonstrated a patient-based sensitivity, specificity, PPV and NPV of 93.33, 96.30, 87.5 and 96.15%, respectively. Pelvic mpMRI showed a LN region-based sensitivity, specificity, PPV and NPV of 96.08, 99.47, 94.23 and 99.65%, respectively. Table 4 demonstrates the detection results of ⁶⁸Ga-PSMA-11 PET-CT and mpMRI for LNMs by the size of the node based on histopathology. The numbers of the short-axis diameter ≤ 10 mm lymphnodes were detected by ⁶⁸Ga-PSMA-11 PET-CT,

### Table 2 Findings in 42 patients at lymphadenectomy

| Number of LN | Mean LN/patient | Number of involved LN | OF | EI | II | CI | PSF | Patients with pN1 stage |
|--------------|-----------------|-----------------------|----|----|----|----|-----|-------------------------|
| 621          | 7.095 (2–15)    | 51 (8.21)             | 15 (29.41) | 20 (39.22) | 11 (21.57) | 5 (9.80) | 0 (0) | 15 (35.71)             |

LN lymph node, pN1 regional LN invaded by micro metastases or ITC, OF obturator fossa, EI external iliac LN, II internal iliac LN, CI common iliac LN, PSF presacral fossa
mpMRI and pathology were 8, 5 and 9, respectively. The numbers of the short-axis diameter > 10 mm lymph-nodes were detected by $^{68}$Ga-PSMA-11 PET-CT, mpMRI and pathology were 41, 44 and 42, respectively. There was no statistical difference for the detection rate of LNMs according to the diameter of the LNMs between $^{68}$Ga-PSMA-11 PET-CT (short-axis diameter $\leq$ 10 mm: 92.75%; short-axis diameter $>$ 10 mm: 97.62%) and mpMRI (short-axis diameter $\leq$ 10 mm: 92.11%; short-axis diameter $>$ 10 mm: 95.65%) in this study.

**Discussion**

LN staging is a crucial element to determine optimal management [14]. Therefore, preoperative accurate assessment of lymph node status is very important in patients with intermediate to high-risk PCa. CT or conventional MRI imaging are commonly used for preoperative LN status evaluation. However, the LN status is largely underestimated with these traditional technique [15, 16]. To date, PLND is considered the most accurate for assessment of nodal involvement, as it provides fresh tissue for pathologic nodal analysis [15]. Nevertheless, this technique is invasive. It is associated with increased lymphocoele/lymphedema rates and venous thromboembolism rates [17]. More advanced imaging techniques demonstrated limited sensitivity and specificity such as $^{11}$C-choline or $^{18}$F-fluorocholine-based combined PET-CT [16, 18]. Therefore, novel accurate and no invasive imaging techniques might be very important in selecting patients that were suitable for PLND with intermediate to high-risk PCa.
The ideal imaging modality should fulfil some prerequisites: accuracy, availability, reproducibility, cost effectiveness, and efficiency. Recent researches have focused on development of new prostate-specific ligands binding to the PSMA for radionuclide imaging and therapy. The exact role of PSMA in the prostate gland is still discussed; however, it has been shown to be several times more active in PCa cells than in normal prostate cells. Moreover, PSMA expression in PCa is highly increased and has been shown to have prognostic relevance [19]. Recently, PET imaging using PSMA ligands specifically targets PCa cells independent of their metabolic state. $^{68}$Ga-PSMA-11 PET/CT is a promising technique for primary prostatic lesions, metastasis disease and biochemical recurrence after definitive treatment of acinar prostate cancer [20].

Although the main interest was evaluation of LN involvement, we firstly evaluated patient characteristics stratified by nodal status. In our study, we found that the PSA value, pT stage at RP, intraprostatic PCa volume and SUV, maximum PCa in patients with LN metastases was significantly higher than patients with no LN metastases (Table 1). The results cueing us that patients of PCa with LN metastases had a greater likelihood of malignant behavior.

Budäus et al. [21] retrospectively evaluated the diagnostic performance of preoperative PSMA PET-CT in a cohort of 30 high-risk PCa patients undergoing RP and ePLND. They overall detected 608 LNs containing 53 LNMs. The overall sensitivity, specificity, PPV, and NPV of $^{68}$Ga-PSMA-11 PET/CT for LNM detection were 33.3, 100, 100, and 69.2%, respectively [21]. However, 42 patients with 621 LNs were resected with a mean number of 7.095 nodes per patient (range 2–15 nodes) in our study. Fifteen patients (35.71%) had a pN1 stage, which corresponds to a total of 51 of 621 LNs (8.21%). Moreover, our study demonstrated a high specificity, sensitivity, PPV, and NPV of $^{68}$Ga-PSMA-11 PET-CT for the detection of LNMs in men with intermediate and high-risk PCa based on per-patient analysis and per LN-analysis. However, the sensitivity and NPV of $^{68}$Ga-PSMA-11 PET/CT for LNM detection in our study is significant better than that of the results of Budäus L. et al. However, the specificity and PPV of $^{68}$Ga-PSMA-11 PET/CT for LNM detection in our study is slightly below that of the results of Budäus L. et al. This may due to the limited number of positive lymph nodes, especially the number of micro-metastases or isolated tumor cells (ITC) in our study. Therefore, the recently developed functional imaging techniques of $^{68}$Ga-PSMA-11 PET-CT might add sufficient sensitivity and specificity to overcome the clinically significant N staging problem. Moreover, PSMA-radioguided surgery using a probe intraoperatively is a promising technique that may be able to detect the location of the LN metastases particularly of small lesions more precisely.

MpMRI, including T1- and T2-weighted imaging, DWI, ADC, DCE and other functional sequences. DWI providing information on tissue cellular density and membrane integrity, and DCE MRI, enabling visualization of vascular permeability and perfusion [7]. Currently, mpMRI is the best imaging method for the detection of significant PCa compared to other imaging methods [12, 15]. Moreover, it has shown a high sensitivity and specificity for the detection and characterisation of LN metastases of some types of cancer [22]. Fortunately, the present retrospective evaluation showed promising results for mpMRI in LN staging of intermediate and high-risk PCa with a calculated sensitivity of 93.33% per-patient analysis and 96.08% per-LN analysis, specificity 96.30% per-patient analysis and 99.47% per-LN analysis, PPV 87.5% per-patient analysis and 94.23% per-LN analysis, NPV 96.15% per-patient analysis and 99.65% per-LN analysis, respectively. The specificity, sensitivity, PPV, and NPV of $^{68}$Ga-PSMA-11 PET-CT is similar to pelvic mpMRI in our study. Thus, there is no incremental value of $^{68}$Ga-PSMA-11 PET-CT over pelvic mpMRI in terms metastatic lymphnode detection in our study. This excellent result of pelvic mpMRI for lymph node staging in our study may due to high-resolution imaging of 3.0-T MR scanner and multiparametric magnetic resonance sequences (T1- and T2- high-resolution weighted imaging, DWI, ADC, and DCE). Moreover, the sensitivity of sub-centimeter lymph-node in both PSMA PET-CT and mpMRI is high and similar may due to less prevalence of histopathology positive sub-centimeter lymphnodes in our study. The results in our study indicated that $^{68}$Ga-PSMA-11 PET-CT and mpMRI both appears to provide helpful additional information in the staging of PCa with intermediate to high metastatic risk. Our study is an important research on the assessment of LN status pre-operative. However, further studies are needed to investigate the possible contribution of $^{68}$Ga-PSMA PET-CT to mpMRI for the primary detection of PCa.

There are limitations associated with this study. First, the selection of patients with intermediate to high probability for LNMs might have overestimated the diagnostic performances of $^{68}$Ga-PSMA-11 PET-CT and mpMRI. Second, presacral fossa LNs were not removed, which might have influenced the sensitivity. Third, since all PET-CT and mpMRI scans were reported by experienced physicians, the present results may not be directly adaptable to clinical practice. Finally, as a small retrospective single center study the results should be confirmed in larger, prospective and multicenter settings.
Conclusions

68Ga-PSMA-11 PET-CT and mpMRI in our study appears to provide helpful additional information in the staging of PCa with intermediate to high metastatic risk. Both mpMRI and 68Ga-PSMA-11 PET-CT have a high specificity, sensitivity, PPV, and NPV for the detection of LNMs in men with intermediate and high-risk PCa. Pre-operative 68Ga-PSMA-11 PET-CT-guided region-based LN dissection represents a suitable approach since it is less time consuming and easier to perform without losing information. However, despite excellent performance, it cannot replace mpMRI that remains excellent for tumoral localization, local evaluation, and lymph node staging.

Abbreviations

mpMRI: multiparametric magnetic resonance imaging; PCa: prostate cancer; RP: radical prostatectomy; PLND: pelvic lymph node dissection; PSMA: prostate-specific membrane antigen; 68Ga-PSMA-11: [68Ga] Glu-urea-Lys(Ahx)-HBED-CC; SUV: standardized uptake value; PPV: positive predictive value; NPV: negative predictive value.

Authors' contributions

QZ, CZ, SMZ, XYL and XZZ performed the data collection for this study. QZ, SMZ and CWZ performed statistical analysis. QZ, SMZ and CWZ completed the written content of the manuscript. QZ and YMD contributed to collection of background information to generate concise argument. CZ, YY, YMD, QLZ, RL, WW and XYL provided significant critical contribution to the analysis and clinical reasoning of the manuscript. HQG and FW conceived of the study, and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

Author details

1 Department of Urology, Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University, 321 Zhongshan Rd., Nanjing 210008, Jiangsu, People’s Republic of China. 2 Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China. 3 Department of Pathology, Drum Tower Hospital, Medical School of Nanjing University, Nanjing 210008, Jiangsu, People’s Republic of China. 4 Department of Radiology, Drum Tower Hospital, Medical School of Nanjing University, Nanjing 210008, Jiangsu, People’s Republic of China.

Acknowledgements

The authors would like to thank all our participants for their gracious participation in this study.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

The datasets supporting the conclusions of this article are available in the Nanjing drum tower hospital Medical Records Room data base (Nanjing, Jiangsu, China) repository.

Consent for publication

Not applicable.

Ethics and consent to participate

Informed consent was obtained for all participants and studies were approved by the Institutional Review Board at Nanjing drum tower hospital (Reference: DT2017028).

Funding

This work was supported by the Nanjing Science and Technology Program (201605013). The funding body had no role in the design of the study, collection, analysis and interpretation of data, or in writing the manuscript.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 21 August 2017 Accepted: 20 October 2017 Published online: 07 November 2017

References

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225–49.
2. Cary KC, Punnen S, Odisho AY, Litwin MS, Saigal CS, Cooperberg MR. Nationally representative trends and geographic variation in treatment of localized prostate cancer: the Urologic Diseases in America project. Prostate Cancer Prostatic Dis. 2015;18(2):149–54.
3. Budiharto T, Joniau S, Lerut E, et al. Prospective evaluation of 11C-choline positron emission tomography/computed tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases. Eur Urol. 2011;60(1):125–30.
4. Cornford F, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer: part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71(4):630–42.
5. Hövels AM, Heesakkers RA, Adang EM, et al. The diagnostic accuracy of CT and MR in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol. 2008;63(4):387–95.
6. Mehralivand S, Bednarova S, Shih JH, et al. Prospective evaluation of prostate imaging reporting and data system, version 2 using the international society of urological pathology prostate cancer grade group system. J Urol. 2017;198:583–90.
7. Borofsky S, Haji-Momenian S, Shah S, Taffel M. Multiparametric MRI of the prostate gland: technical aspects. Future Oncol. 2016;12(21):2445–62.
8. Afshtar-Oromieh A, Zechmann CM, Malcher A, et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41(1):11–20.
9. Herlemann A, Wenter V, Kretschmer A, et al. (68)Ga-PSMA positron emission tomography/computed tomography provides accurate staging of lymph node regions prior to lymph node dissection in patients with prostate cancer. Eur Urol. 2016;70(4):553–7.
10. Silver DA, Pelllicer I, Fair WR, Heston WD, Cordono-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3(1):81–5.
11. Zhang Q, Wang W, Yang R, et al. Free-hand transperineal targeted prostate biopsy with real-time fusion imaging of multiparametric magnetic resonance imaging and transrectal ultrasound: single-center experience in China. Int Urol Nephrol. 2015;47(5):727–33.
12. Zhang Q, Wang W, Zhang B, et al. Comparison of free-hand transperineal mpMRI/TRUS fusion-guided biopsy with transperineal 12-core systematic biopsy for the diagnosis of prostate cancer: a single-center prospective study in China. Int Urol Nephrol. 2017;49(3):439–48.
13. Zhang S, Shao G, Cui C, et al. 68Ga-PSMA-11 PET/CT for prostate cancer staging and risk stratification in Chinese patients. Oncotarget. 2017;8(7):12247–58.
14. Van Poppel H, Joniau S. An analysis of radical prostatectomy in advanced stage and high-grade prostate cancer. Eur Urol. 2008;53(2):253–9.
15. Eiber M, Beer AJ, Holzapfel K, et al. Preliminary results for characterization of pelvic lymph nodes in patients with prostate cancer by diffusion-weighted MR imaging. Invest Radiol. 2010;45(1):15–23.
16. Pinaquy JB, De Clermont-Galleran H, Pasticier G, et al. Comparative effectiveness of [(18)F]-fluorocholine PET-CT and pelvic MRI with diffusion-weighted imaging for staging in patients with high-risk prostate cancer. Prostate. 2015;75(3):323–31.
17. Incerti E, Mapelli P, Gionalli L, Picchio M. PET imaging for lymph node dissection in prostate cancer. World J Urol. 2017;35(4):507–15.
18. Heicappell R, Muller-Matthei V, Reinhardt M, et al. Staging of pelvic lymph nodes in neoplasms of the bladder and prostate by positron emission tomography with 2-[(18)F]-2-deoxy-o-glucose. Eur Urol. 1999;36(6):582–7.
19. Kawakami M, Nakayama J. Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Cancer Res. 1997;57(12):2321–4.

20. Meredith G, Wong D, Yaxley J, et al. The use of (68)Ga-PSMA PET CT in men with biochemical recurrence after definitive treatment of acinar prostate cancer. BJU Int. 2016;118(Suppl 3):49–55.

21. Budäus L, Leyh-Bannurah SR, Salomon G, et al. Initial experience of (68)Ga-PSMA PET/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy. Eur Urol. 2016;69(3):393–6.

22. Vandecaveye V, De Keyzer F, Vander PV, et al. Head and neck squamous cell carcinoma: value of diffusion-weighted MRI imaging for nodal staging. Radiology. 2009;251(1):134–46.